1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMassVentures provides 'Stage II' grants to the most promising 'Stage I' winners from the previous year, along with business guidance for SBIR Phase II companies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: SBIR Phase II companies that were previous 'Stage I' winners. Confirm the full requirements in the official notice before applying.
The current listing shows $200,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
SBIR Phase II companies grants and business guidance (Stage II) is funded by MassVentures. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Small Business Transition Grant for New Entrepreneurs (SBIR) — R43 Phase I is a grant from the National Institutes of Health (NIH) that funds early-stage scientific innovation by small businesses aiming to bring biomedical breakthroughs to the commercial marketplace. The Phase I award supports feasibility research, evaluating technical merit and commercial potential of proposed innovations. Eligible applicants are U.S. small business concerns, particularly new entrepreneurs, applying under PAR-24-131. Awards cover up to approximately $306,872 in total costs for Phase I. The most recent deadline is September 5, 2026.
NIH SBIR/STTR Parent SBIR (R43/R44) Clinical Trial Not Allowed (PA-24-245) is sponsored by National Institutes of Health (NIH). The NIH SBIR program supports small businesses developing innovative technologies that address health-related challenges through Phase I and Phase II funding, focusing on establishing technical feasibility, research and development, and advancing toward commercialization.